Glioblastoma tumors originate from glial precursor cells exhibiting marked cellular pleomorphism, nuclear atypia, and high mitotic activity. Characteristic histological features include pseudopalisading necrosis and microvascular proliferation.
Molecular classification distinguishes primary glioblastoma (developing de novo) from secondary glioblastoma (arising from lower-grade gliomas). Key genetic alterations involve EGFR amplification, PTEN mutations, and IDH wild-type status, with methylation patterns influencing treatment response and prognosis.
Clinical Presentation and Symptom Patterns
Symptoms vary based on tumor location and growth rate. Focal neurological deficits may include motor weakness, sensory disturbances, or language impairments.
Increased intracranial pressure typically causes headaches, nausea, vomiting, and papilledema. Seizures occur in approximately 30-50% of patients, while cognitive changes involve memory impairment, executive dysfunction, and personality alterations. Symptom progression often occurs rapidly over weeks to months.
Diagnostic Imaging and Assessment Protocols
MRI with contrast enhancement remains the gold standard for initial detection, typically showing irregular enhancing lesions with central necrosis.
Advanced techniques including perfusion MRI and MR spectroscopy help differentiate glioblastoma from other brain lesions. Surgical biopsy provides definitive diagnosis through histopathological examination, while molecular profiling guides treatment selection and prognostic stratification.
Comprehensive Treatment Strategies
Maximal safe surgical resection represents the initial treatment approach, though complete removal proves difficult due to infiltrative growth patterns. Postoperative radiotherapy with concurrent temozolomide chemotherapy constitutes standard adjuvant treatment.
Tumor treating fields therapy provides additional survival benefit when combined with maintenance chemotherapy. Bevacizumab targets angiogenesis in recurrent disease, while various targeted therapies address specific molecular alterations.
Emerging Therapeutic Approaches
Novel treatment strategies focus on overcoming therapeutic resistance mechanisms. Immunotherapy approaches including checkpoint inhibitors and CAR-T cells aim to enhance anti-tumor immune responses. Oncolytic viruses selectively target malignant cells, while drug delivery systems bypass the blood-brain barrier.
Gene therapy strategies manipulate tumor suppressor pathways, and clinical trials investigate combination therapies targeting multiple resistance mechanisms simultaneously.
Palliative Care and Quality of Life Considerations
Comprehensive supportive care manages symptoms and treatment side effects effectively. Corticosteroids control peritumoral edema, while antiepileptic drugs prevent seizures.
Neurorehabilitation addresses functional deficits, and palliative services optimize quality of life throughout disease progression. Early integration of palliative care improves symptom control and patient satisfaction.
Related topics:
